Strategic analysis on medical device regulation and compliance engineering.
For most low-risk medical devices, regulatory success is not determined by whether FDA clearance is possible, but by how the regulatory pathway is framed from the beginning. Pathway selection influ...
Medical device labeling and Instructions for Use (IFU) are often treated as downstream documentation tasks—something finalized after pathway selection, predicate identification, and testing decisio...
Intended use and indications for use are two of the most misunderstood concepts in medical device regulation. They are often treated as interchangeable, but they serve different regulatory purposes...
Bringing a medical device to market does not end with FDA authorization. For manufacturers seeking hospital adoption, reimbursement strategy often becomes the next critical bottleneck. Even clinica...
Bringing a medical device to market is not simply a question of whether it will be cleared, approved, or authorized, but how you get there. Regulatory pathway selection, device classification, and ...
Early engagement with the FDA can shape the success or failure of a medical device submission long before a 510(k), De Novo, or PMA is filed. The FDA’s Pre-Submission and Q-Submission programs are ...
The FDA’s Electronic Submission Template and Resource (eSTAR) has fundamentally changed how 510(k) submissions are prepared, validated, and reviewed. What was once a largely document-driven process...